Evidence map›Paper›PMID 41804072›Full record

ArticleAdvanced biology2026

Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance.

Allison Jorgensen, Daniel W Vermeer, Euihye Jung, Caitlin S Williamson, Dalia K Omran, Lauren E Schwartz, Ju-Yoon Yoon, Jeffrey Barr, Ashley L Tetlow, Camille V Trinidad and 3 more

Abstract read
In one paragraph

Article in Advanced biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Allison JorgensenCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.
Daniel W VermeerCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.
Euihye JungPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Caitlin S WilliamsonCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.
Dalia K OmranPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Lauren E SchwartzDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Ju-Yoon YoonDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Jeffrey BarrCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.
Ashley L TetlowDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Camille V TrinidadDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Ronny DrapkinPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Paola D VermeerCancer Biology and Immunotherapies Group, Sanford Research, Sioux Falls, South Dakota, USA.ORCID 0000-0003-2370-8223

Funding

Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Diane E Mahoney · 2019 to 2026
$21.5M
SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5M
Pilot Project ProgramP30GM145398 · NIGMS · SANFORD RESEARCH/USD · PI W KEITH MISKIMINS · 2023 to 2026
$6.2M
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered MicrosystemR01CA260132 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K., ZENG, YONG · 2021 to 2025
$3.4M
Intra-tumoral neurons contribute to head and neck cancer painR01DE032712 · NIDCR · SANFORD RESEARCH/USD · PI Paola Drapkin Vermeer · 2023 to 2026
$1.8M
Belinda Sue Fund for Ovarian Cancer Awareness and ResearchClaneil FoundationDr. Miriam and Sheldon G. Adelson Medical Research FoundationHonorable Tina Brozman FoundationNational Institutes of Health P50 CA228991NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA260132NIDCR NIH HHS 1R01DE032712NIDCR NIH HHS R01 DE032712NIGMS NIH HHS P20 GM130423NIGMS NIH HHS P20GM130423NIGMS NIH HHS P30 GM145398NIH HHS P30GM145398Ovarian Cancer Research Fund AlliancePredicine
6 · The paper itself

Abstract

Patients with densely innervated tumors suffer with poor outcomes, thus identifying them could define a cohort that could benefit from aggressive treatments. Most cases and deaths from ovarian cancer are associated with high-grade serous ovarian carcinoma (HGSOC). We immunohistochemically analyzed the histological subtypes of ovarian cancer (high-grade serous, low-grade serous, clear cell, mucinous, and endometrioid) for nerves; only HGSOCs were densely innervated. We previously defined that tumor-released small extracellular vesicles (sEVs) recruit nerves to the tumor bed and thus tested whether the difference in nerve infiltration amongst ovarian cancers was associated with sEVs. Using an in vitro neurite outgrowth assay, we found that HGSOC sEVs harbored robust neurite outgrowth activity. Importantly, sEVs from fallopian tube cell lines (the primary cell of origin of HGSOC) predominantly lacked this activity. Implantation of a syngeneic mouse model of HGSOC into transgenic mice lacking tumor-infiltrating nerves slowed tumor growth, sensitized disease to carboplatin, and improved survival. Consistent with this, we show that recurrent, treatment-resistant disease in patients is significantly more innervated than its matched naïve (untreated) malignancy. Taken together, these data identify dense nerve infiltration of HGSOCs and show that innervation contributes to treatment resistance.

Indexed as

Drug Resistance, NeoplasmOvarian NeoplasmsAnimalsCell Line, TumorExtracellular VesiclesFemaleHumansMiceMice, Transgenicneurite outgrowthnociceptor neuronsovarian cancersmall extracellular vesiclestumor‐infiltrating nerves

Identifiers

PMID41804072
PMCPMC13004430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.